IL276871B1 - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents
Dosage forms and methods for enantiomerically enriched or pure bupropionInfo
- Publication number
- IL276871B1 IL276871B1 IL276871A IL27687120A IL276871B1 IL 276871 B1 IL276871 B1 IL 276871B1 IL 276871 A IL276871 A IL 276871A IL 27687120 A IL27687120 A IL 27687120A IL 276871 B1 IL276871 B1 IL 276871B1
- Authority
- IL
- Israel
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- pure bupropion
- bupropion
- Prior art date
Links
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title 1
- 229960001058 bupropion Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL276871A IL276871A (en) | 2020-10-29 |
| IL276871B1 true IL276871B1 (en) | 2024-07-01 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276871A IL276871B1 (en) | 2018-02-23 | 2020-08-23 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (en) |
| JP (3) | JP2021513998A (en) |
| KR (3) | KR20210003091A (en) |
| CN (1) | CN112087999A (en) |
| AU (2) | AU2019223187B2 (en) |
| BR (1) | BR112020017179A2 (en) |
| CA (1) | CA3092076A1 (en) |
| CL (1) | CL2020002166A1 (en) |
| CR (1) | CR20200415A (en) |
| EC (1) | ECSP20060179A (en) |
| IL (1) | IL276871B1 (en) |
| MA (1) | MA51914A (en) |
| MX (2) | MX2020008704A (en) |
| NI (1) | NI202000056A (en) |
| NZ (1) | NZ767378A (en) |
| PE (1) | PE20211752A1 (en) |
| SG (1) | SG11202008056SA (en) |
| WO (1) | WO2019165379A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CN114423417A (en) * | 2019-09-20 | 2022-04-29 | 艾克萨姆治疗公司 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052341A1 (en) * | 1999-03-01 | 2002-05-02 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
| US20160030420A1 (en) * | 2013-11-05 | 2016-02-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20170304230A1 (en) * | 2013-11-05 | 2017-10-26 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| BRPI0318456B8 (en) * | 2003-08-08 | 2021-05-25 | Biovail Laboratories Int Srl | tablet with modified release |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/en active Application Filing
- 2019-02-25 CR CR20200415A patent/CR20200415A/en unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/en active Pending
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/en unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/en not_active IP Right Cessation
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/en unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/en active Pending
- 2019-02-25 MA MA051914A patent/MA51914A/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/en unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/en unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/en unknown
- 2020-08-23 IL IL276871A patent/IL276871B1/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/en unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521A1/en active Pending
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/en active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052341A1 (en) * | 1999-03-01 | 2002-05-02 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
| US20160030420A1 (en) * | 2013-11-05 | 2016-02-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20170304230A1 (en) * | 2013-11-05 | 2017-10-26 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024075655A (en) | 2024-06-04 |
| SG11202008056SA (en) | 2020-09-29 |
| EP3755312A1 (en) | 2020-12-30 |
| KR20240091043A (en) | 2024-06-21 |
| AU2019223187B2 (en) | 2022-07-28 |
| AU2022204521A1 (en) | 2022-07-21 |
| AU2019223187A1 (en) | 2020-09-17 |
| JP2021513998A (en) | 2021-06-03 |
| KR20210003091A (en) | 2021-01-11 |
| MX2023009281A (en) | 2023-08-17 |
| KR20230075531A (en) | 2023-05-31 |
| JP2022153638A (en) | 2022-10-12 |
| NZ767378A (en) | 2024-03-22 |
| BR112020017179A2 (en) | 2020-12-22 |
| WO2019165379A1 (en) | 2019-08-29 |
| CR20200415A (en) | 2021-02-03 |
| EP3755312A4 (en) | 2022-03-16 |
| NI202000056A (en) | 2021-01-11 |
| MA51914A (en) | 2020-12-30 |
| CL2020002166A1 (en) | 2020-10-23 |
| MX2020008704A (en) | 2020-12-07 |
| CN112087999A (en) | 2020-12-15 |
| IL276871A (en) | 2020-10-29 |
| ECSP20060179A (en) | 2020-12-31 |
| CA3092076A1 (en) | 2019-08-29 |
| PE20211752A1 (en) | 2021-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
| IL275055A (en) | Triabody, preparation method and use thereof | |
| IL276871B1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| IL282600A (en) | Composition and method for treating the lungs | |
| EP3324975A4 (en) | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof | |
| IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| IL282007A (en) | Medicament for the treatment of chronic cough | |
| IL272385A (en) | Drug compound and purification methods thereof | |
| EP3429598A4 (en) | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder | |
| PL3285755T3 (en) | Creatine hydrochloride for the treatment of huntington's disease | |
| ZA201900707B (en) | New treatment for the non alcoholic steatohepatitis and fibrosis | |
| HUE053871T2 (en) | Dental implant and dental implant system | |
| IL291514A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| PH12016502284B1 (en) | Cough medicine containing ambroxol hydrochloride | |
| SG10201606557RA (en) | Oxygen-enriched water composition, biocompatible composition comprising the same, and methods of preparing and using the same | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201908229D0 (en) | Microneedles and methods for the manufacture thereof | |
| IL254793A0 (en) | A composition for the treatment of neuropathies and/or neuropathic pain | |
| SG11202107799XA (en) | Enriched water formulations and processes for preparation thereof | |
| IL282671A (en) | Therapeutic methods and compositions | |
| SG11202001855QA (en) | Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol | |
| PT3576795T (en) | Oral thyroid therapeutic agent | |
| GB201818904D0 (en) | New formulations and methods | |
| GB201806133D0 (en) | Methods and medical uses |